Acceder

Publicaciones - ONCOLOGÍA CLÍNICA Y TRASLACIONAL

Cargando...
Vergote I, Perez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martinez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Hogdall E, Farinas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. PubMed PMID: 37669480.
AÑO: 2023; IF: 45.3
37669480
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez Garcia J, Petru E, Kocian R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier E, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. PubMed PMID: 37643382; PubMed Central PMCID: PMC10602539.
AÑO: 2023; IF: 45.3
37643382
Manzano JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, Medina Martinez J, Quindos M, Garcia-Castano A, Fernandez O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macias Cerrolaza JA, Gil-Arnaiz I, Lorente D, Rodriguez-Lescure A, Perez VN, Lopez Castro R, Gramaje MG, Puertolas T, Rodriguez Moreno JF, Espasa Font L, Belaustegui Ferrandez G, Cerezuela-Fuentes P. Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study. Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888. Online ahead of print. PubMed PMID: 36988401.
AÑO: 2023; IF: 2.2
36988401
Antonio CCP, Alida GG, Elena GG, Rocío GS, Jerónimo MG, Luis ARJ, Aníbal ND, Francisco BV, Jesús GRÁ, Pablo RR, José GM. Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial. Ann Surg Oncol. 2022 Apr;29(4):2617-2625. doi: 10.1245/s10434-021-11087-7. Epub 2021 Nov 23. PubMed PMID: 34812982.
AÑO: 2022; IF: 3.7
34812982
Aguado de la Rosa C, Cruz Castellanos P, Lázaro-Quintela M, Dómine M, Vázquez Estévez S, López-Vivanco G, Fírvida Pérez JL, Alonso Romero JL, Ferrera Delgado L, García Girón C, Diz Taín P, Álvarez Álvarez R, Mut Sanchís P, Fernández Cantón I, Manrique Abós I, Martínez Aguillo M, Gómez-Aldaraví Gutiérrez L, Ortega Granados AL, Álvarez Cabellos R, García Sebastián A, García Sifuentes LF, Reguart N. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022 Nov;173:83-93. doi: 10.1016/j.lungcan.2022.09.010. Epub 2022 Sep 19. PubMed PMID: 36162227.
AÑO: 2022; IF: 5.3
36162227
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

ONCOLOGÍA CLÍNICA Y TRASLACIONAL